D-1063-2020 Class III Terminated

Recalled by Breckenridge Pharmaceutical, Inc — Berlin, CT

FDA drug recall D-1063-2020 was initiated by Breckenridge Pharmaceutical, Inc on Feb 24, 2020 and is designated Class III. Reason for recall: Failed Impurities/Degradation Specifications: Out-of-specification results obtained for impurities during stability testing. The recall status is terminated (terminated Aug 31, 2020). Affected quantity: 900 Vials.

Recall details

Product Type
Drugs
Report Date
Mar 4, 2020
Initiation Date
Feb 24, 2020
Termination Date
Aug 31, 2020
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
900 Vials

Product description

Zoledronic Acid Injection 5 mg/100 mL (0.05 mg/mL), Solution for Intravenous Infusion, Sterile Solution, 100 mL Single - Dose Vial per Carton, Rx Only, Distributed by: Breckenridge Pharmaceutical, Inc., Boca Raton, FL 33487, Manufactured by: Pharmaceutics International, Inc., Hunt Valley, MD 21031, NDC 51991-064-98.

Reason for recall

Failed Impurities/Degradation Specifications: Out-of-specification results obtained for impurities during stability testing.

Distribution pattern

Nationwide in the U.S.

Code information

Lot # 5553.044E; 5553.044F, Exp. 04/30/2021

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-1063-2020
openFDA file date
Nov 10, 2026
Loaded by RegDataLab
Nov 11, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-1063-2020. Report a data issue: hello@regdatalab.com.